Alivus Life Sciences Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Glenmark Life Sciences Limited (to 2025)
1
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 29, 2027The maintenance fee for Process for the preparation of tavaborole (US 10,457,695) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Process for the preparation of apremilast (US 10,494,342) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 5, 2027The maintenance fee for Amorphous and crystalline forms of aprepitant and processes for the preparation thereof (US 9,227,958) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Process for preparation of dapagliflozin (US 10,556,877) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,097,729 | Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,227,958 | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,670,160 | Process for the preparation of tofacitinib and intermediates thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,550,735 | Process for the preparation of ivacaftor and solvates thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,840,456 | Process for preparation of dimethyl fumarate In force · From the USPTO record | In force | From the USPTO record | |
| US 10,556,877 | Process for preparation of dapagliflozin In force · From the USPTO record | In force | From the USPTO record | |
| US 10,494,342 | Process for the preparation of apremilast In force · From the USPTO record | In force | From the USPTO record | |
| US 10,457,695 | Process for the preparation of tavaborole In force · From the USPTO record | In force | From the USPTO record | |
| US 11,447,448 | Process for the preparation of solriamfetol and salt thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,365,649 | Process for the preparation of brivaracetam In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 1 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.